Publications

This pre-clinical study found that an mRNA vaccine against varicella-zoster virus (VZV), the cause of shingles, was highly immunogenic in non-human primates and generated comparably robust responses to an approved protein vaccine and markedly higher responses compared to an approved live attenuated vaccine.

This pre-clinical study shows that an mRNA vaccine against HIV induced potent and broad T cell responses, supporting the ability of mRNA technology to accelerate HIV vaccine discovery.

This pre-clinical study demonstrates the ability of mRNA vaccines to protect against congenital viral infection in mice.

Pre-clinical study of mRNA encoding an antibody against chikungunya virus protected against infection, showed dose-dependent protein expression and no dose-limiting toxicities in vivo.

Modified mRNA vaccines delivered with a proprietary Moderna LNP show enhanced tolerability and comparable immunogenicity relative to legacy LNP.

This preclinical study with a LNP-formulated, modified mRNA vaccine demonstrates 100% survival and higher protective antibody titers than previously observed with viral vector vaccines.

Results in non-human primates characterize the response of immune-suppressive cells to vaccination, expanding our understanding of the mechanisms underlying vaccine immunogenicity versus reactogenicity.

This research demonstrates that LNP-formulated mRNA vaccines can induce protection against viral placental and fetal damage in mouse models, critical for vaccines against viruses that exhibit vertical transmission.

This in vivo research demonstrates that a mRNA vaccine encoding components of a subviral particle can prevent disease.

Data from a Phase 1a/b study of mRNA encoding for vascular endothelial growth factor A (VEGF-A) shows tolerability, protein expression and protein pharmacology in human subjects and its potential for use as a regenerative therapeutic.

In mouse models, the intradermal administration of mRNA encoding for VEGF-A can induce a localized, sustained, and reproducible biological response, including blood vessel formation and oxygenation to accelerate diabetic wound healing.

(This publication is the work of a Moderna strategic collaborator and Moderna assumes no responsibility for the information or statements therein).

This foundational paper establishes that direct injection of modified mRNA in mice can induce local physiological changes and could be an effective approach for regenerative therapeutics.

This pre-clinical study shows mRNA encoding the alpha 1-antitrypsin (AAT) protein led to functional protein expression in human AAT deficient patient hepatocytes and mouse models of AAT deficiency, supporting the translation of mRNA in hepatocytes and secretion of AAT protein into systemic circulation as a potential replacement therapy.

This publication outlines a translational modeling framework that can be used to describe the effects of mRNA therapy for acute intermittent porphyria (AIP) in preclinical models and support development in humans.

This pre-clinical study shows that repeat dosing of mRNA encoding ARG1 delivered via lipid nanoparticles was able to treat mouse models of arginase deficiency and supports the potential of mRNA therapeutics to treat rare metabolic disorders.

Creation of a genetic mouse model that resembles much of the clinical phenotype of rare disease patients demonstrates the value of translational research in developing novel therapies for rare diseases.

A systematic review of the global epidemiology literature on MMA confirms that MMA and its subtypes are ultra-rare with similar detection rates across geographic regions with the exception of the Middle East, where the disease is more frequent.

A systematic review of the global epidemiology literature on PA confirms that PA is an ultra-rare disorder with similar detection rates across geographic regions with the exception of the Middle East, where the disease is more frequent.

Results in a mouse disease model suggest that repeat systemic administration of LNP-formulated mRNA can elicit intracellular protein expression in hepatocytes for rapid and sustained amelioration of disease.

This review highlights the potential for RNA cancer immunotherapies, including mRNA applications in cancer vaccines and immune modulation.

This pre-clinical study showed mRNA encoding for IL-12 administered intratumorally promoted a Th1 tumor microenvironment and robust systemic anti-tumor immune response in mouse models, suggesting the potential of local IL-12 mRNA therapy to drive tumor regression while mitigating systemic tolerability challenges.

This study shows that both modifying nucleotide chemistry as well as engineering the mRNA production process to reduce double-stranded RNA are important for controlling innate immune activation, providing important insights for mRNA therapies.

This study elucidates the fundamental mechanism of accelerated blood clearance of LNPs, informing improved designs for nanoparticle delivery systems.

This study describes a novel analytical method to characterize mRNA sequences with great specificity and to detect minor sequence impurities to inform technical development of mRNA therapeutics.

Non-human primate and rodent studies demonstrate the potential for repeat dosing of mRNA safely and at therapeutically relevant levels with proprietary Moderna lipids.

In vivo studies with systemic delivery of modified mRNA in an industry standard LNP demonstrate therapeutic levels of protein expression and predictable pharmacology and toxicology.

This chapter highlights recent advances in the delivery of nucleotide therapeutics and their application to mRNA therapeutics.

This paper explores the molecular mechanisms through which modified nucleosides can promote translation efficiency, which is critical to designing potent mRNA therapeutics.